Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia) for Crohn's Disease

Trial Profile

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia) for Crohn's Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms SECURE
  • Sponsors UCB; UCB Biosciences
  • Most Recent Events

    • 09 May 2023 Results of post-hoc analysis of data from the SECURE registry assessing the long term real world pregnancy outcomes of patients exposed to CZP versus those exposed to other CD treatments presented at the Digestive Disease Week 2023
    • 23 May 2021 Results of post hoc analysis assessing the non-melanoma skin cancer risk by incidence rate ratio in patients with crohns disease, presented at the Digestive Disease Week 2021.
    • 28 Sep 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top